Lexicon Completes EOP2 Meeting for Pilavapadin in Diabetic Peripheral Neuropathic Pain.

Lexicon Pharmaceuticals completed an End-of-Phase 2 meeting with the FDA for pilavapadin in diabetic peripheral neuropathic pain (DPNP). The FDA raised no objections to advancing pilavapadin into Phase 3 development, which will include two registrational studies comparing the 10 mg daily dose to placebo. The primary endpoint will be the change in average daily pain score from baseline to Week 12.